TD Asset Management Inc. increased its position in shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 7.3% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 426,225 shares of the biopharmaceutical company’s stock after buying an additional 29,138 shares during the quarter. TD Asset Management Inc. owned 0.19% of Alexion Pharmaceuticals worth $59,795,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. Teachers Retirement System of The State of Kentucky lifted its stake in Alexion Pharmaceuticals by 35.1% during the third quarter. Teachers Retirement System of The State of Kentucky now owns 240,022 shares of the biopharmaceutical company’s stock worth $33,672,000 after purchasing an additional 62,400 shares during the period. Norinchukin Bank The lifted its stake in Alexion Pharmaceuticals by 6.6% during the third quarter. Norinchukin Bank The now owns 16,613 shares of the biopharmaceutical company’s stock worth $2,331,000 after purchasing an additional 1,029 shares during the period. ING Groep NV lifted its stake in Alexion Pharmaceuticals by 426.6% during the third quarter. ING Groep NV now owns 49,882 shares of the biopharmaceutical company’s stock worth $6,998,000 after purchasing an additional 40,410 shares during the period. Icon Advisers Inc. Co. lifted its stake in Alexion Pharmaceuticals by 107.3% during the third quarter. Icon Advisers Inc. Co. now owns 34,000 shares of the biopharmaceutical company’s stock worth $4,770,000 after purchasing an additional 17,600 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in Alexion Pharmaceuticals by 13.9% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 48,360 shares of the biopharmaceutical company’s stock worth $6,784,000 after purchasing an additional 5,909 shares during the period. 95.80% of the stock is currently owned by institutional investors and hedge funds.

Shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) opened at $108.61 on Friday. The company has a quick ratio of 2.51, a current ratio of 2.96 and a debt-to-equity ratio of 0.35. The firm has a market cap of $24,260.00, a P/E ratio of 22.21, a P/E/G ratio of 1.18 and a beta of 1.22. Alexion Pharmaceuticals, Inc. has a fifty-two week low of $96.18 and a fifty-two week high of $149.34.

Alexion Pharmaceuticals (NASDAQ:ALXN) last issued its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.44 earnings per share for the quarter, beating analysts’ consensus estimates of $1.32 by $0.12. The business had revenue of $859.00 million during the quarter, compared to analyst estimates of $864.34 million. Alexion Pharmaceuticals had a net margin of 14.57% and a return on equity of 12.55%. Alexion Pharmaceuticals’s revenue for the quarter was up 7.5% compared to the same quarter last year. During the same quarter last year, the business posted $1.23 earnings per share. research analysts expect that Alexion Pharmaceuticals, Inc. will post 4.81 EPS for the current year.

A number of brokerages have commented on ALXN. Leerink Swann restated a “buy” rating and set a $182.00 price target on shares of Alexion Pharmaceuticals in a research note on Monday, September 25th. Zacks Investment Research cut shares of Alexion Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Monday, October 2nd. BidaskClub upgraded shares of Alexion Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, August 5th. Royal Bank Of Canada began coverage on shares of Alexion Pharmaceuticals in a research note on Thursday, September 14th. They set an “outperform” rating and a $161.00 price target for the company. Finally, BMO Capital Markets restated an “outperform” rating and set a $173.00 price target (up previously from $168.00) on shares of Alexion Pharmaceuticals in a research note on Wednesday, September 13th. Six analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and two have given a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $154.01.

In related news, EVP Julie O’neill sold 11,160 shares of the firm’s stock in a transaction that occurred on Monday, August 28th. The shares were sold at an average price of $140.00, for a total value of $1,562,400.00. Following the completion of the sale, the executive vice president now owns 26,704 shares of the company’s stock, valued at $3,738,560. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Ann M. Veneman sold 835 shares of the firm’s stock in a transaction that occurred on Tuesday, September 5th. The shares were sold at an average price of $145.81, for a total transaction of $121,751.35. Following the completion of the sale, the director now directly owns 5,480 shares of the company’s stock, valued at approximately $799,038.80. The disclosure for this sale can be found here. In the last three months, insiders sold 16,490 shares of company stock valued at $2,337,251. 4.35% of the stock is currently owned by company insiders.

ILLEGAL ACTIVITY NOTICE: This piece of content was first published by Watch List News and is owned by of Watch List News. If you are accessing this piece of content on another publication, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark law. The correct version of this piece of content can be accessed at https://www.watchlistnews.com/td-asset-management-inc-purchases-29138-shares-of-alexion-pharmaceuticals-inc-alxn/1726756.html.

About Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.